Alternative efficacy-predicting markers for paclitaxel instead of CHFR in non-small cell lung cancer

Cancer Biology and Therapy

Volumn 10, Issue 9, 2010, Pages 933-941

  Takeshita, Masafumi ^a   Koga, Takaomi ^a   Takayama, Koichi ^a   Yano, Tokujiro ^a   Maehara, Yoshihiko ^a   Nakanishi, Yoichi ^a   Sueishi, Katsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

CHFR; EGFR; NSCLC; Paclitaxel; Smoking habit

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PACLITAXEL; SUCCINATE DEHYDROGENASE; UBIQUITIN PROTEIN LIGASE E3;

AGED; ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIVITY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METHYLATION; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM PROTEINS; PACLITAXEL; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; SMOKING; SUCCINATE DEHYDROGENASE; TUMOR MARKERS, BIOLOGICAL;

EID: 78549282146     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.9.13320     Document Type: Article

References (32)

1. Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJ. Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer 2002; 2:37.
2. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007; 18:317-23.
3. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-8.
4. Sweeney CJ, Zhu J, Sandler AB, Schiller J, Belani CP, Langer C, et al. Outcome of patients with a performance status of 2 in eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer 2001; 92:2639-47.
5. Rigas JR. Taxane-platinum combinations in advanced non-small cell lung cancer: a review. Oncologist 2004; 9:16-23.
6. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355:983-91. (Pubitemid 44343542)
7. Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006; 24:4731-7.
8. Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998; 10:123-30.
9. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport and cell death. J Clin Oncol 1999; 17:1061-70.
10. Scolnick DM, Halazonetis TD. Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature 2000; 406:430-5.
11. Satoh A, Toyota M, Itoh F, Sasaki Y, Suzuki H, Ogi K, et al. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 2003; 63:8606-13.
12. Banno K, Yanokura M, Kawaguchi M, Kuwabara Y, Akiyoshi J, Kobayashi Y, et al. Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes. Int J Oncol 2007; 31:713-20.
13. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-500.
14. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-39.
15. Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA 2007; 104:18654-9.
16. Toyota M, Suzuki H, Yamashita T, Hirata K, Imai K, Tokino T, et al. Cancer epigenomics: implications of DNA methylation in personalized cancer therapy. Cancer Sci 2009; 100:787-91.
17. Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H, Imai K. Inactivation of the 14-3-3sigma gene is associated with 5′ CpG island hypermethylation in human cancers. Cancer Res 2000; 60:4353-7.
18. Koga Y, Kitajima Y, Miyoshi A, Sato K, Sato S, Miyazaki K. The significance of aberrant CHFR methylation for clinical response to microtubule inhibitors in gastric cancer. J Gastroenterol 2006; 41:133-9.
19. Yanokura M, Banno K, Kawaguchi M, Hirao N, Hirasawa A, Susumu N, et al. Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer. Oncol Rep 2007; 17:41-8.
20. Ogi K, Toyota M, Mita H, Satoh A, Kashima L, Sasaki Y, et al. Small interfering RNA-induced CHFR silencing sensitizes oral squamous cell cancer cells to microtubule inhibitors. Cancer Biol Ther 2005; 4:773-80. (Pubitemid 41351179)
21. Tsao AS, Liu D, Lee JJ, Spitz M, Hong WK. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer 2006; 106:2428-36.
22. Takeshita M, Koga T, Takayama K, Kouso H, Nishimura-Ikeda Y, Yoshino I, et al. CHFR expression is preferentially impaired in smoking-related squamous cell carcinoma of the lung and the diminished expression significantly harms outcomes. Int J Cancer 2008; 123:1623-30.
23. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-57.
24. Weng D, Song X, Xing H, Ma X, Xia X, Weng Y, et al. Implication of the Akt2/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells. Cancer Lett 2009; 273:257-65.
25. Mabuchi S, Ohmichi M, Kimura A, Hisamoto K, Hayakawa J, Nishio Y, et al. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem 2002; 277:33490-500.
26. Liu X, Shi Y, Woods KW, Hessler P, Kroeger P, Wilsbacher J, et al. Akt inhibitor a-443654 interferes with mitotic progression by regulating aurora a kinase expression. Neoplasia 2008; 10:828-37.
27. Takeuchi H, Baba H, Inutsuka S, Takahashi I, Kusumoto H, Maehara Y, et al. Antitumor chemosensitivity differs between clinical sarcoma and adenocarcinoma tissues. Anticancer Res 1994; 14:169-71.
28. Takenaka T, Yoshino I, Kouso H, Ohba T, Yohena T, Osoegawa A, et al. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int J Cancer 2007; 121:895-900.
29. Koga T, Hashimoto S, Sugio K, Yoshino I, Mojtahedzadeh S, Matsuo Y, et al. Clinicopathological and molecular evidence indicating the independence of bronchioloalveolar components from other subtypes of human peripheral lung adenocarcinoma. Clin Cancer Res 2001; 7:1730-8.
30. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111:1710-7.
31. Koga T, Takeshita M, Yano T, Maehara Y, Sueishi K. CHFR hypermethylation and EGFR mutation are mutually exclusive and exhibit contrastive clinical backgrounds and outcomes in non-small-cell lung cancer. Int J Cancer 2010.
32. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-9. (Pubitemid 17064313)